Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer-Reference-Cited by-同舟云学术

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

Published:2021-10-29 Issue:10 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kazmi Farasat¹,Shrestha Nipun²,Booth Stephen¹,Dodwell David³,Aroldi Francesca¹,Foord Thomas⁴,Nicholson Brian D⁵,Heesen Philip⁶,Lord Simon¹,Yeoh Kheng-Wei⁷,Blagden Sarah¹

Affiliation:

1. Department of Oncology; University of Oxford; Oxford UK

2. Department of Primary Care and Mental Health; University of Liverpool; Liverpool UK

3. Nuffield Department of Population Health; University of Oxford; Oxford UK

4. University of Oxford; Oxford UK

5. Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK

6. University of Zurich; Zurich Switzerland

7. Radiation Oncology; National Cancer Centre; Singapore Singapore

Publisher

Wiley

Subject

Pharmacology (medical)

Reference50 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;NCI: Journal of the National Cancer Institute,1993

2. Phase I trials as valid therapeutic options for patients with cancer;Adashek;Nature Reviews. Clinical Oncology,2019

3. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer;André;New England Journal of Medicine,2019

4. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without Cetuximab for stage III to IV head and neck carcinoma: RTOG (0522);Ang;Journal of Clinical Oncology,2014

5. Emerging agents and new mutations in EGFR-mutant lung cancer;Ayeni;Clinical Cancer Research,2015